Clinical Trials Logo

Clinical Trial Summary

This is an outpatient, single center, between-group, double blind, placebo controlled design. Approximately 120 adolescents and adult patients will be randomized to either have their treatment augmented with Cannabidiol Oral Solution (CBD) or with a matching CBD placebo for 8 weeks. The study will examine CBD as an augmentation strategy in early psychosis. It is hypothesized that CBD will improve symptoms, neurocognition, markers of inflammation and eating behaviors. Importantly, moderators and mediators of the CBD effects will be explored.


Clinical Trial Description

Participants will be randomly assigned in a 1:1 ratio to receive CBD or matching Placebo as an add-on to antipsychotic medication in an 8 week double blind trial. In this study, Cannabidiol Oral Solution (CBD) product will be used. This product is manufactured and supplied by GW Pharmaceuticals. The formulation is a 100 mg/mL solution. The CBD compound will be dosed at 1000mg/day administered in two divided doses. The dose of CBD was selected based on previous controlled trials that demonstrate the efficacy of CBD in patients with schizophrenia. The maximum duration of the study from screening to follow up of outcomes and adverse events will be approximately 8 weeks. Participants will receive either the CBD or placebo within this eight.weeks and will also complete pre-treatment, midpoint (week 4) and post-treatment testing (week 8). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04411225
Study type Interventional
Source University of California, San Diego
Contact Kristin Cadenhead
Phone 619-543-6445
Email KCADENHEAD@UCSD.EDU
Status Recruiting
Phase Phase 3
Start date June 1, 2022
Completion date October 30, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06032182 - PSYCHE Cognitive Remediation & Social Recovery Study N/A
Active, not recruiting NCT06192602 - Effects of an Acceptance-based Medication Adherence Therapy for Recent-onset Psychosis N/A
Completed NCT04592042 - Intervention to Improve Coping With Negative Emotions in Patients With Psychosis (Feel-Good-Study) Early Phase 1
Completed NCT04373590 - Decision-making and Decision Support Among Emerging Adults With First Episode Psychosis N/A
Active, not recruiting NCT04166019 - Effect of a Peer-led Self-management Program for Recent-onset Psychosis N/A
Recruiting NCT04317807 - R33: Levetiracetam in Early Psychosis Phase 2